TURBT术后吡柔比星膀胱灌注预防肿瘤复发的疗效分析

[目的]评价吡柔比星（THP）膀胱灌注预防膀胱肿瘤TURBT术后复发的疗效和安全性。[方法]1999年11月-2003年10月，膀胱肿瘤TURBT术后患者63例，术后接受THP30mg膀胱灌注治疗，随访12-53个月。[结果]膀胱癌TURBT术后THP膀胱灌注，术后1年未复发率89．8％，术后2年未复发率83．1％，术后3年未复发率76．3％；膀胱灌注THP副反应发生率为28．57％。[结论]应用THP30mg／50mL（600μg／mL），TURBT术后尽早膀胱灌注，膀胱内保留30min，采用为期1年的短期疗程，对于预防膀胱肿瘤TURBT术后复发有较好的疗效。

Intravesical instillation of pirarubicin (THP) in prophylactic treatment after transurethral resection of bladder cancer

[Objective] To evaluate the effectiveness and safety of intravesical instillation of THP after transurethral resection of bladder cancer(TURBT).[Methods] From Nov.1999 to Oct.2003,a total of 63 patients were treated with intravesical instillation of THP after TURBT,the patients were followed up by cystscopy for 12~53 months.[Results] The non-recurrence rates at 1,2 and 3 years were 89.8%,83.1% and 76.3%,respectively.The side effect rate was 28.57%.[Conclusions] Our findings demonstrated that short-term(1 ye...